Manufacturer
Novartis NDC Codes
Finished products listed with the FDA under labeler names that contain “Novartis”.
Products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Diovan HCTvalsartan and hydrochlorothiazide | Valsartan 160 mg/1; Hydrochlorothiazide 25 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0383 |
| Diovan HCTvalsartan and hydrochlorothiazide | Valsartan 320 mg/1; Hydrochlorothiazide 12.5 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0471 |
| Diovan HCTvalsartan and hydrochlorothiazide | Valsartan 320 mg/1; Hydrochlorothiazide 25 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0472 |
| Egatentriclabendazole | Triclabendazole 250 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0937 |
| Entrestosacubitril and valsartan | Sacubitril 24 mg/1; Valsartan 26 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0659 |
| Entrestosacubitril and valsartan | Sacubitril 97 mg/1; Valsartan 103 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0696 |
| Entrestosacubitril and valsartan | Sacubitril 49 mg/1; Valsartan 51 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0777 |
| Entrestosacubitril and valsartan | Sacubitril 6 mg/1; Valsartan 6 mg/1 | PelletOral | Novartis Pharmaceuticals Corporation | 0078-1231 |
| Entrestosacubitril and valsartan | Sacubitril 15 mg/1; Valsartan 16 mg/1 | PelletOral | Novartis Pharmaceuticals Corporation | 0078-1238 |
| Entrestosacubitril and valsartan | Sacubitril 24 mg/1; Valsartan 26 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-9659 |
| Entrestosacubitril and valsartan | Sacubitril 49 mg/1; Valsartan 51 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-9777 |
| Exelonrivastigmine | Rivastigmine 4.6 mg/24h | Patch, Extended releaseTransdermal | Novartis Pharmaceuticals Corporation | 0078-0501 |
| Exelonrivastigmine | Rivastigmine 9.5 mg/24h | Patch, Extended releaseTransdermal | Novartis Pharmaceuticals Corporation | 0078-0502 |
| Exelonrivastigmine | Rivastigmine 13.3 mg/24h | Patch, Extended releaseTransdermal | Novartis Pharmaceuticals Corporation | 0078-0503 |
| Exforgeamlodipine besylate and valsartan | Amlodipine besylate 5 mg/1; Valsartan 160 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0488 |
| Exforgeamlodipine besylate and valsartan | Amlodipine besylate 10 mg/1; Valsartan 160 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0489 |
| Exforgeamlodipine besylate and valsartan | Amlodipine besylate 5 mg/1; Valsartan 320 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0490 |
| Exforgeamlodipine besylate and valsartan | Amlodipine besylate 10 mg/1; Valsartan 320 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0491 |
| Exforge HCTamlodipine valsartan and hydrochlorothiazide | Amlodipine besylate 5 mg/1 + 2 more ingredients | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0559 |
| Exforge HCTamlodipine valsartan and hydrochlorothiazide | Amlodipine besylate 5 mg/1 + 2 more ingredients | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0560 |
| Exforge HCTamlodipine valsartan and hydrochlorothiazide | Amlodipine besylate 10 mg/1 + 2 more ingredients | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0561 |
| Exforge HCTamlodipine valsartan and hydrochlorothiazide | Amlodipine besylate 10 mg/1 + 2 more ingredients | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0562 |
| Exforge HCTamlodipine valsartan and hydrochlorothiazide | Amlodipine besylate 10 mg/1 + 2 more ingredients | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0563 |
| Exjadedeferasirox | Deferasirox 125 mg/1 | Tablet, For suspensionOral | Novartis Pharmaceuticals Corporation | 0078-0468 |
| Exjadedeferasirox | Deferasirox 250 mg/1 | Tablet, For suspensionOral | Novartis Pharmaceuticals Corporation | 0078-0469 |